Impact of a Hospital Pharmacist's Intervention on FENO (Fractional Exhaled Nitric Oxide) in Asthmatic Patients
Impact of a Hospital Pharmacist's Intervention on FENO (Fractional Exhaled Nitric Oxide) in Asthmatic Patients
The impact of a pharmacist's intervention on asthma control has now been well demonstrated,
 but its effect on inflammatory markers of FENO (Fractional exhaled nitric oxide) in asthmatic
 patients has been little studied in the literature. The aim of this study is to investigate
 the impact of a pharmacist's intervention on FENO in patients seen in clinical practice by a
 pneumologist in a secondary university center.
Inclusion Criteria:

 -  Adult asthmatics (definition of asthma: FEV1 [forced expiratory volume in 1 second]
 reversibility of at least 12% and 200 mL after 400 mcg of salbutamol and/or PC20M
 [provocative concentration of methacholine causing a 20% fall in FEV1]<16 mg/mL)

 -  unchanged or increased dose of inhaled corticosteroids prescribed by the pneumologist
 at the visit

 -  FENO (fractional exhaled nitric oxide) > or = 25 ppb

 Exclusion Criteria:

 -  Treatment with oral corticosteroids to treat an asthma exacerbation within 4 weeks
 before the visit with the pneumologist

 Exclusion Criteria during the study:

 -  Change of the dose of ICS (inhaled corticosteroids) during the follow-up of 3 months
 after the pharmacist's intervention

 -  Severe asthma exacerbation requiring oral corticosteroids within the 4 weeks before
 the follow-up visit (3 months after the pharmacist's intervention)